cas 1421372-67-9|| where to buy N1-(2-(Dimethylamino)ethyl)-5-methoxy-N1-methyl-N4-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)-2-nitrobenzene-1,4-diamine

Product Name:N1-(2-(Dimethylamino)ethyl)-5-methoxy-N1-methyl-N4-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)-2-nitrobenzene-1,4-diamine

IUPAC Name:N1-[2-(dimethylamino)ethyl]-5-methoxy-N1-methyl-N4-[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]-2-nitrobenzene-1,4-diamine

Packing Unit	Available Stock	Price($)
CM147322-5g	in stock	œǠƴ
CM147322-10g	in stock	œȅƴ
CM147322-25g	in stock	ǆȅŸ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1421372-67-9 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:1421372-67-9; Molecular Formula:C25H29N7O3; Melting Point:-; Smiles Code:O=[N+](C1=CC(NC2=NC=CC(C3=CN(C)C4=C3C=CC=C4)=N2)=C(OC)C=C1N(CCN(C)C)C)[O-]; Density:

: Catalog Number:CM147322; Molecular Weight:475.55; Boiling Point:695.0±65.0°C at 760 mmHg; MDL No:MFCD28167947; Storage:Keep in dark place, store at 2-8°C.

: Indoles; Indole is a compound of pyrrole and benzene in parallel, also known as benzopyrrole. There are two combinations of pyrrole and benzene, called indole and isoindole, respectively. Many derivatives of indole have physiological and pharmacological activities, and can synthesize vasodilators, antihistamines, antipyretic analgesics, etc. in medicine, so indole is also a very important heterocyclic compound.

: Osimertinib; TAGRISSO (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial.
TAGRISSO (osimertinib) is a third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including against central nervous system metastases. It is the first and only EGFR TKI recommended by NCCN Guidelines as an adjuvant treatment option for completely resected stage IB-IIIA, stage IIIB (T3, N2) EGFRm (exon 19 deletion, exon 21 L858R mutation) NSCLC.